PE20221445A1 - Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 - Google Patents
Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1Info
- Publication number
- PE20221445A1 PE20221445A1 PE2022000616A PE2022000616A PE20221445A1 PE 20221445 A1 PE20221445 A1 PE 20221445A1 PE 2022000616 A PE2022000616 A PE 2022000616A PE 2022000616 A PE2022000616 A PE 2022000616A PE 20221445 A1 PE20221445 A1 PE 20221445A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- compounds
- treatment
- diseases related
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
En la presente invencion se describen compuestos que se utilizan como inmunomoduladores, los cuales tienen la Formula (I) al igual que sus estereoisomeros y sales farmaceuticamente aceptables. Estructuralmente, A es un grupo heteroarilo de 5 a 10 miembros que pueden sustituirse con 1 o 5 miembros del grupo que consiste en halogeno, alquilo C1-3, etc.; X1 es alquileno C1-3, que puede sustituirse con 1 o 2 miembros del grupo de C1-2, CO2H, etc.; R2a y R2b se seleccionan independientemente del grupo de H, alquilo C1-8, entre otros, y se combinan para formar un anillo espirociclico; R3 y R4 se seleccionan independientemente del grupo que consiste en H, F, Cl, etc.; el subindice 'n' es 0, 1, 2 o 3; R3a, R6, R7 y R8 se seleccionan del grupo que consiste en H, Cl, alquilo C1-3, etc; y Z se selecciona de un anillo heterociclico monociclico, biciclico o espirociclico no aromatico, y de un anillo heteroarilico monociclico de 5 o 6 miembros. Ademas, se describen metodos para la preparacion y uso de estos compuestos para el tratamiento de enfermedades relacionadas con el ligando PD-L1 y se mencionan metodos para la obtencion de compuestos de Formula (II) con los compuestos de Formula (I) mencionados, los catalizadores Cloro (Cl), Bromo (Br) o Yodo (I), con los reactivos tipo borato e hidruro y en condiciones del tipo de la reaccion de Suzuki, para que tambien puedan utilizarse en el tratamiento de enfermedades relacionadas con PD-L1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962915779P | 2019-10-16 | 2019-10-16 | |
US202063042796P | 2020-06-23 | 2020-06-23 | |
US202063057460P | 2020-07-28 | 2020-07-28 | |
PCT/US2020/055672 WO2021076691A1 (en) | 2019-10-16 | 2020-10-15 | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221445A1 true PE20221445A1 (es) | 2022-09-21 |
Family
ID=75538873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000616A PE20221445A1 (es) | 2019-10-16 | 2020-10-15 | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
Country Status (17)
Country | Link |
---|---|
US (2) | US11713307B2 (es) |
EP (1) | EP4045036A4 (es) |
JP (1) | JP2022551973A (es) |
KR (1) | KR20220084119A (es) |
CN (1) | CN114585359A (es) |
AU (1) | AU2020368393A1 (es) |
BR (1) | BR112022006018A2 (es) |
CA (1) | CA3152329A1 (es) |
CL (1) | CL2022000956A1 (es) |
CO (1) | CO2022004723A2 (es) |
CR (1) | CR20220215A (es) |
EC (1) | ECSP22038478A (es) |
IL (1) | IL291642A (es) |
MX (1) | MX2022004451A (es) |
PE (1) | PE20221445A1 (es) |
TW (1) | TW202128651A (es) |
WO (1) | WO2021076691A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
CA3152714A1 (en) | 2019-10-16 | 2021-04-22 | Pingchen Fan | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
JP2023531970A (ja) * | 2020-06-23 | 2023-07-26 | ケモセントリックス, インコーポレイテッド | ヘテロアリール-ビフェニルアミド誘導体を用いて癌を処置する方法 |
EP4337202A1 (en) * | 2021-06-18 | 2024-03-20 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
CN115010658B (zh) * | 2022-05-11 | 2023-06-27 | 南方医科大学 | 一种化合物及其制备方法与应用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2402317T1 (sl) | 2006-03-31 | 2013-10-30 | Novartis Ag | DGAT inhibitor |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
SG10201510307WA (en) | 2011-11-14 | 2016-01-28 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
US8993756B2 (en) | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
PL3041827T3 (pl) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
PL3041828T3 (pl) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Technologies Limited | Pochodne 1,3,4-oksadiazolu i 1,3,4-tiadiazolu jako immunomodulatory |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
US20180118718A1 (en) | 2015-05-13 | 2018-05-03 | Selvita S.A. | Substituted Quinoxaline Derivatives |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
PL3394033T3 (pl) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
EP3459925B1 (en) | 2016-05-23 | 2021-08-11 | Tianjin Chase Sun Pharmaceutical Co., Ltd. | Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative |
MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
MX2018016273A (es) | 2016-06-20 | 2019-07-04 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
CA3029857C (en) | 2016-07-05 | 2023-07-04 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
CA3029991A1 (en) | 2016-07-08 | 2018-01-11 | Bristol-Myers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2018045142A1 (en) | 2016-09-02 | 2018-03-08 | Polaris Pharmaceuticals, Inc. | Immune checkpoint inhibitors, compositions and methods thereof |
JP7106572B2 (ja) | 2016-12-20 | 2022-07-26 | ブリストル-マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な化合物 |
ES2899402T3 (es) * | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
CN110582493B (zh) | 2016-12-22 | 2024-03-08 | 因赛特公司 | 作为免疫调节剂的苯并噁唑衍生物 |
WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
CN106674136B (zh) | 2016-12-23 | 2019-07-02 | 中国医科大学 | 嘧啶类抗肿瘤化合物及其制备方法 |
US10654815B2 (en) | 2016-12-29 | 2020-05-19 | Shenzhen Chipscreen Biosciences Co., Ltd. | Urea compound and preparation method and application thereof |
CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
ES2961550T3 (es) | 2017-03-27 | 2024-03-12 | Bristol Myers Squibb Co | Derivados de isoquinolina sustituidos como inmunomoduladores |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018196768A1 (zh) | 2017-04-26 | 2018-11-01 | 南京圣和药业股份有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
CN109400522B (zh) | 2017-08-18 | 2023-04-28 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
US11492375B2 (en) | 2017-10-03 | 2022-11-08 | Bristol-Myers Squibb Company | Cyclic peptide immunomodulators |
CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
WO2019120297A1 (zh) | 2017-12-22 | 2019-06-27 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
US11384048B2 (en) | 2017-12-29 | 2022-07-12 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
US11414418B2 (en) | 2018-01-23 | 2022-08-16 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
EP3750887A4 (en) | 2018-02-05 | 2021-10-20 | Abbisko Therapeutics Co., Ltd. | BIARYLE DERIVATIVE, ITS PREPARATION PROCESS, AND ITS PHARMACEUTICAL APPLICATION |
UA126458C2 (uk) * | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
WO2019169123A1 (en) | 2018-03-01 | 2019-09-06 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pd1/pd-l1相互作用/活性化の阻害剤としての二環式化合物 |
WO2019174533A1 (zh) | 2018-03-13 | 2019-09-19 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
SG11202009440WA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
JP2021520342A (ja) | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | 免疫調節物質、組成物及びそれらの方法 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
WO2020011209A1 (zh) | 2018-07-11 | 2020-01-16 | 上海和誉生物医药科技有限公司 | 免疫抑制剂及其制备方法和在药学上的应用 |
CN112384500A (zh) | 2018-07-12 | 2021-02-19 | 贝达药业股份有限公司 | 免疫调节剂及其组合物和制备方法 |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2020015716A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
CN112424194B (zh) | 2018-07-19 | 2024-02-06 | 贝达药业股份有限公司 | 免疫调节剂及其组合物和制备方法 |
CN112638899B (zh) | 2018-08-01 | 2023-09-05 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
CA3139526A1 (en) * | 2019-05-15 | 2020-11-19 | Chemocentryx, Inc. | Triaryl compounds for treatment of pd-l1 diseases |
CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
KR20220024701A (ko) | 2019-06-20 | 2022-03-03 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 화합물 |
CA3152714A1 (en) | 2019-10-16 | 2021-04-22 | Pingchen Fan | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
JP2023531970A (ja) * | 2020-06-23 | 2023-07-26 | ケモセントリックス, インコーポレイテッド | ヘテロアリール-ビフェニルアミド誘導体を用いて癌を処置する方法 |
-
2020
- 2020-10-15 US US17/071,077 patent/US11713307B2/en active Active
- 2020-10-15 CN CN202080073061.4A patent/CN114585359A/zh active Pending
- 2020-10-15 BR BR112022006018A patent/BR112022006018A2/pt unknown
- 2020-10-15 AU AU2020368393A patent/AU2020368393A1/en active Pending
- 2020-10-15 JP JP2022522680A patent/JP2022551973A/ja active Pending
- 2020-10-15 KR KR1020227016263A patent/KR20220084119A/ko unknown
- 2020-10-15 CA CA3152329A patent/CA3152329A1/en active Pending
- 2020-10-15 EP EP20877065.1A patent/EP4045036A4/en active Pending
- 2020-10-15 PE PE2022000616A patent/PE20221445A1/es unknown
- 2020-10-15 MX MX2022004451A patent/MX2022004451A/es unknown
- 2020-10-15 CR CR20220215A patent/CR20220215A/es unknown
- 2020-10-15 WO PCT/US2020/055672 patent/WO2021076691A1/en unknown
- 2020-10-16 TW TW109135946A patent/TW202128651A/zh unknown
-
2022
- 2022-03-23 IL IL291642A patent/IL291642A/en unknown
- 2022-04-13 CO CONC2022/0004723A patent/CO2022004723A2/es unknown
- 2022-04-14 CL CL2022000956A patent/CL2022000956A1/es unknown
- 2022-05-13 EC ECSENADI202238478A patent/ECSP22038478A/es unknown
-
2023
- 2023-06-12 US US18/333,262 patent/US20230322731A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2022000956A1 (es) | 2023-01-13 |
US20210130325A1 (en) | 2021-05-06 |
CO2022004723A2 (es) | 2022-04-29 |
MX2022004451A (es) | 2022-05-03 |
CR20220215A (es) | 2022-09-14 |
JP2022551973A (ja) | 2022-12-14 |
TW202128651A (zh) | 2021-08-01 |
ECSP22038478A (es) | 2022-06-30 |
AU2020368393A1 (en) | 2022-04-21 |
IL291642A (en) | 2022-05-01 |
US11713307B2 (en) | 2023-08-01 |
EP4045036A1 (en) | 2022-08-24 |
US20230322731A1 (en) | 2023-10-12 |
EP4045036A4 (en) | 2023-11-15 |
CN114585359A (zh) | 2022-06-03 |
KR20220084119A (ko) | 2022-06-21 |
WO2021076691A1 (en) | 2021-04-22 |
CA3152329A1 (en) | 2021-04-22 |
BR112022006018A2 (pt) | 2022-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221445A1 (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
DOP2019000104A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer | |
AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
UY38752A (es) | Derivados de benzisoxazol sulfonamida | |
CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
DOP2016000045A (es) | Compuestos de benzoxaborol tricíclicos y usos de los mismos | |
AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
ES2171884T3 (es) | Compuestos de quinazolina. | |
ES2603570T3 (es) | Preparación de colonoscopia | |
SV2004001548A (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR072353A1 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasa | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
DOP2019000228A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
ECSP22038509A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
CR20190379A (es) | Moduladores del receptor de estrógeno | |
CO2019003894A2 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia |